ReviewFrontiers in pharmacology2022
An insight into the neuroprotective and anti-neuroinflammatory effects and mechanisms of
Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 44 citations in OpenAlex.
- FermentedPharmaceutical biology · 2026Article
- Untargeted LC-MS/MS Metabolite Profiling of Wild, Field-Domesticated and Tissue-Cultured Rhizomes of the Endangered Medicinal FernLife (Basel, Switzerland) · 2026Article
- Selective elimination of amyloid-β-induced senescent neuroblastoma cells by Moringa oleifera leaf extract.Scientific reports · 2026Article
- Biophysical characterization of polyphenol aggregates in Moringa oleifera leaves water extract: stability and surface exposure effect on antioxidant activity under dilution.European biophysics journal : EBJ · 2026Article
- Therapeutic Potential ofJournal of inflammation research · 2026Review
- Beyond Antioxidant Activity: Redox-Inflammatory Network Modulation as a Framework for the Multi-Organ Pharmacology ofJournal of experimental pharmacology · 2026Review
- Integrative metabolomics using untargeted UHPLC-MS/MS and chemometrics identifies optimal maturity stage ofPeerJ · 2026Article
- Moringa Oleifera Enhances the Cell Proliferation and Neural Differentiation of B65 and PC12 Cells.Advanced biomedical research · 2026Article
- Ameliorative Effect of Moringa oleifera Against CUMS-Induced Anxiety in Rats: β-Catenin and 5-HTMolecular neurobiology · 2025Article
- α-Cyclodextrin/Moringin Impacts Actin Cytoskeleton Dynamics with Potential Implications for Synaptic Organization: A Preliminary Transcriptomic Study in NSC-34 Motor Neurons.International journal of molecular sciences · 2025Article
- Glucosinolate Metabolites and Brain Health: An Updated Review on Their Potential Benefits in Neurodegenerative, Neurodevelopmental, and Psychiatric Disorders.Antioxidants (Basel, Switzerland) · 2025Review
- Exploring the therapeutic role of Moringa oleifera in neurodegeneration: antioxidant, anti-inflammatory, and neuroprotective mechanisms.Inflammopharmacology · 2025Review
- Moringa oleifera and Its Biochemical Compounds: Potential Multi-targeted Therapeutic Agents Against COVID-19 and Associated Cancer Progression.Biochemical genetics · 2025Review
- Article
- Unveiling the Miracle Tree: Therapeutic Potential ofBiomedicines · 2025Review
- Correlations Between Amelioration of Rotenone-Induced Parkinson's Symptoms byInternational journal of molecular sciences · 2025Article
- Identification of Chlorogenic Acids fromACS omega · 2025Article
- Mini review of plant products as food supplement against MSG-induced liver injury: antioxidant, oxidative stress and histological prospects.Frontiers in pharmacology · 2025Review
- Natural Products and Their Neuroprotective Effects in Degenerative Brain Diseases: A Comprehensive Review.International journal of molecular sciences · 2024Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegenerative diseases (NDs) are sporadic maladies that affect patients' lives with progressive neurological disabilities and reduced quality of life. Neuroinflammation and oxidative reaction are among the pivotal factors for neurodegenerative conditions, contributing to the progression of NDs, such as Parkinson's disease (PD), Alzheimer's disease (AD), multiple sclerosis (MS) and Huntington's disease (HD). Management of NDs is still less than optimum due to its wide range of causative factors and influences, such as lifestyle, genetic variants, and environmental aspects. The neuroprotective and anti-neuroinflammatory activities of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.